Gene Silencing and Editing Strategies for Neurodegenerative Diseases
Neurodegenerative diseases (NDs) are a heterogeneous group of disorders affecting the central nervous system. Despite significant differences in their causes, neuropathological abnormalities, and clinical outcomes, some similarities can be found among them, as for example: 1) frequent aggregation an...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2018 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (115 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993548693604498 |
---|---|
ctrlnum |
(CKB)4920000000094114 (oapen)https://directory.doabooks.org/handle/20.500.12854/48351 (EXLCZ)994920000000094114 |
collection |
bib_alma |
record_format |
marc |
spelling |
Clévio Nóbrega auth Gene Silencing and Editing Strategies for Neurodegenerative Diseases Frontiers Media SA 2018 1 electronic resource (115 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics Neurodegenerative diseases (NDs) are a heterogeneous group of disorders affecting the central nervous system. Despite significant differences in their causes, neuropathological abnormalities, and clinical outcomes, some similarities can be found among them, as for example: 1) frequent aggregation and deposition of misfolded proteins, 2) common molecular mechanisms leading to neurodegeneration, and 3) certain overlap in symptoms and clinical features. To date, there is no cure that could stop or delay the progression of these diseases. The advent of advanced gene therapy techniques such as gene silencing and gene editing opened a new avenue for the development of therapeutic strategies for NDs. The discovery of the RNA interference (RNAi) mechanism, in 1998, by Andrew Fire and Craig Mello allowed an important boost to the gene therapy field, providing a potential therapeutic strategy to treat inherited dominant genetic disorders. The use of small RNA sequences to control the expression of disease-causing genes rapidly implemented in the preclinical studies for different diseases. In the field of NDs, several successful studies using this technology proved its potential as a therapeutic option. However, issues like the type of delivery system (non-viral versus viral) or the potential toxicity of the small RNA molecules, made the translation of gene silencing therapeutics to human application very slow and difficult. Recently, a new hope in the gene therapy field emerged with the development of gene editing techniques like TALENs or CRISPR/Cas9 systems. The opportunity of editing or deleting gene sequences drove the scientific community euphoric, with an enormous increase in the number of published studies using this type of techniques. Recently, the first clinical trial using one of these systems was approved in China. For NDs, gene-editing technology also represents an important therapeutic option, and the first preclinical studies are now being published, showing the potential accomplishment for this technology. English Gene silencing Long non-coding RNAs RNA interference Neurodegenerative diseases CRISPR/Cas9 Neurodegeneration Gene editing Antisense oligonucleotides Neuroinflammation iPS cells 2-88945-551-3 Sandro Alves auth |
language |
English |
format |
eBook |
author |
Clévio Nóbrega |
spellingShingle |
Clévio Nóbrega Gene Silencing and Editing Strategies for Neurodegenerative Diseases Frontiers Research Topics |
author_facet |
Clévio Nóbrega Sandro Alves |
author_variant |
c n cn |
author2 |
Sandro Alves |
author2_variant |
s a sa |
author_sort |
Clévio Nóbrega |
title |
Gene Silencing and Editing Strategies for Neurodegenerative Diseases |
title_full |
Gene Silencing and Editing Strategies for Neurodegenerative Diseases |
title_fullStr |
Gene Silencing and Editing Strategies for Neurodegenerative Diseases |
title_full_unstemmed |
Gene Silencing and Editing Strategies for Neurodegenerative Diseases |
title_auth |
Gene Silencing and Editing Strategies for Neurodegenerative Diseases |
title_new |
Gene Silencing and Editing Strategies for Neurodegenerative Diseases |
title_sort |
gene silencing and editing strategies for neurodegenerative diseases |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2018 |
physical |
1 electronic resource (115 p.) |
isbn |
2-88945-551-3 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT clevionobrega genesilencingandeditingstrategiesforneurodegenerativediseases AT sandroalves genesilencingandeditingstrategiesforneurodegenerativediseases |
status_str |
n |
ids_txt_mv |
(CKB)4920000000094114 (oapen)https://directory.doabooks.org/handle/20.500.12854/48351 (EXLCZ)994920000000094114 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
Gene Silencing and Editing Strategies for Neurodegenerative Diseases |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1787551700151697408 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03225nam-a2200397z--4500</leader><controlfield tag="001">993548693604498</controlfield><controlfield tag="005">20231214133100.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2018 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4920000000094114</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/48351</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994920000000094114</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Clévio Nóbrega</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Gene Silencing and Editing Strategies for Neurodegenerative Diseases</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (115 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Neurodegenerative diseases (NDs) are a heterogeneous group of disorders affecting the central nervous system. Despite significant differences in their causes, neuropathological abnormalities, and clinical outcomes, some similarities can be found among them, as for example: 1) frequent aggregation and deposition of misfolded proteins, 2) common molecular mechanisms leading to neurodegeneration, and 3) certain overlap in symptoms and clinical features. To date, there is no cure that could stop or delay the progression of these diseases. The advent of advanced gene therapy techniques such as gene silencing and gene editing opened a new avenue for the development of therapeutic strategies for NDs. The discovery of the RNA interference (RNAi) mechanism, in 1998, by Andrew Fire and Craig Mello allowed an important boost to the gene therapy field, providing a potential therapeutic strategy to treat inherited dominant genetic disorders. The use of small RNA sequences to control the expression of disease-causing genes rapidly implemented in the preclinical studies for different diseases. In the field of NDs, several successful studies using this technology proved its potential as a therapeutic option. However, issues like the type of delivery system (non-viral versus viral) or the potential toxicity of the small RNA molecules, made the translation of gene silencing therapeutics to human application very slow and difficult. Recently, a new hope in the gene therapy field emerged with the development of gene editing techniques like TALENs or CRISPR/Cas9 systems. The opportunity of editing or deleting gene sequences drove the scientific community euphoric, with an enormous increase in the number of published studies using this type of techniques. Recently, the first clinical trial using one of these systems was approved in China. For NDs, gene-editing technology also represents an important therapeutic option, and the first preclinical studies are now being published, showing the potential accomplishment for this technology.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Gene silencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Long non-coding RNAs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RNA interference</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Neurodegenerative diseases</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CRISPR/Cas9</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Neurodegeneration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Gene editing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Antisense oligonucleotides</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Neuroinflammation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">iPS cells</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88945-551-3</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sandro Alves</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:42:22 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2019-11-10 04:18:40 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338850630004498&Force_direct=true</subfield><subfield code="Z">5338850630004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338850630004498</subfield></datafield></record></collection> |